Meanwhile, Given that the clinical advancement of adavosertib has been constrained by dose-limiting toxicities (particularly hematologic adverse effects) [32–34], we systematically evaluated its therapeutic window across multiple cellular models including normal lung epithelial cells, monocytes, T cells, and lung cancer cell lines harboring wild-type KRAS or non-G12C KRAS mutations (Supplementary Fig. S1C). This evidence concerns the gene KRAS and lung cancer.